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Abstract
Background: Strongyloidiasis may cause a life-threatening disease in immunosuppressed patients. This can only be
prevented by effective cure of chronic infections. Direct parasitologic exams are not sensitive enough to prove cure if
negative. We used an indirect immune fluorescent antibody test (IFAT) along with direct methods for patient inclusion and
efficacy assessment.
Methodology/Principal Findings: Prospective, randomized, open label, phase III trial conducted at the Centre for Tropical
Diseases (Verona, Italy) to compare efficacy and safety of ivermectin (single dose, 200 mg/kg) and thiabendazole (two daily
doses of 25 mg/Kg for two days) to cure strongyloidiasis. The first patient was recruited on 6
th December, 2004. Follow-up
visit of the last patient was on 11
th January, 2007. Consenting patients responding to inclusion criteria were randomly
assigned to one of the treatment arms. Primary outcome was: negative direct and indirect (IFAT) tests at follow-up (4 to 6
months after treatment) or subjects with negative direct test and drop of two or more IFAT titers. Considering 198 patients
who concluded follow-up, efficacy was 56.6% for ivermectin and 52.2% for thiabendazole (p=0.53). If the analysis is
restricted to 92 patients with IFAT titer 80 or more before treatment (virtually 100% specific), efficacy would be 68.1% for
ivermectin and 68.9% for thiabendazole (p=0.93). Considering direct parasitological diagnosis only, efficacy would be
85.7% for ivermectin and 94.6% for thiabendazole (p=0.21). In ivermectin arm, mild to moderate side effects were observed
in 24/115 patients (20.9%), versus 79/108 (73.1%) in thiabendazole arm (p=0.00).
Conclusion: No significant difference in efficacy was observed, while side effects were far more frequent in thiabendazole
arm. Ivermectin is the drug of choice, but efficacy of single dose is suboptimal. Different dose schedules should be assessed
by future, larger studies.
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Introduction
Strongyloidiasis is a chronic, soil-transmitted infection caused by
Strongyloides stercoralis, a helminth with a worldwide distribution,
primarily in tropical and subtropical regions. Foci of low
endemicity are also reported in temperate climates, such as the
Mediterranean Coast, mostly among elderly patients [1,2].
Prevalence data indicate that 30–100 million people are infected,
but the figure is presumably underestimated [3].
Due to a peculiar life cycle that includes autoinfection
(maintenance of parasitism in the absence of any further exposure
to an external source), the infection can persist indefinitely, usually
with mild and aspecific symptoms [3–6]. Nevertheless, dissemi-
nated strongyloidiasis, a life-threatening condition, may occur in
case of immunosuppression [7,8]. A suboptimal efficacy of the
therapy of chronic strongyloidiasis may result in the persistence of
the infection, with the potential risk of disseminated disease at any
time. Several reported cases of fatal, disseminated disease had
previously been treated and apparently cured [7,9,10].
Ivermectin is currently considered the best therapeutic option
[11,12]: trials comparing ivermectin and albendazole demonstrat-
ed unsatisfactory efficacy of the latter [13–16], while small sized
trials comparing thiabendazole and ivermectin showed similar
efficacy, but better tolerability of the latter [17,18].
All trials conducted so far have exclusively relied on direct
methods [17–22]. Therefore, the efficacy of any regimen could
have been overestimated, because negative stool tests after
treatment are no proof of eradication of the infection: the
sensitivity of direct methods is largely unsatisfactory [3,23,24]. On
the other hand, serology has been suggested as a reliable tool to
monitor response to treatment [25–30].
This study was meant to compare the efficacy of ivermectin, admini-
stered as a single dose of 200 mg/kg, and thiabendazole, administered
in two daily doses of 25 mg/Kg for two days, to cure strongyloidiasis.
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The protocol for this trial and supporting CONSORT checklist
are available as supporting information: see Checklist S1 and
Protocol S1.
Study design and participants
This was a prospective, randomized, open label, phase III trial,
carried out at the Centre for Tropical Diseases (CTD), Sacro
Cuore Hospital, Negrar (Verona, Italy). Eligible patients were
male and female subjects older than 5 years and weighing .15 kg,
currently living in a non-endemic area; they had to have a
diagnosis of strongyloidiasis established by indirect immune
fluorescent antibody test (IFAT).
Exclusion criteria were: pregnancy or breastfeeding; CNS
diseases; disseminated strongyloidiasis; immunodeficiency (malig-
nancies, chemotherapy or other immunosuppressive treatments);
planned travel to endemic countries before follow-up; lack of
informed consent.
HIV positive subjects were excluded if CD4+ count was lower
than 400/ml.
Ethics
This research was conducted in full accordance to the Ethical
Principles for Medical Research Involving Human Subjects as
expressed in the Declaration of Helsinki and following amend-
ments. Eligible patients were asked to meet the study investigator,
who gave detailed explanation of the study protocol according to
the patient information sheet and requested for written consent
from the patient or, in case of minors, from her/his parent(s)/
guardians. The study protocol was approved by the local Ethics
Committee (Sacro Cuore Hospital Ethics Committee, 5
th August,
2004). All interventions (including unscheduled visits) were at no
charge to the patients.
Interventions
Potentially eligible subjects attending the study clinic were
identified through laboratory diagnosis of S. stercoralis infection as
defined above. Indirect immune fluorescent antibody test (IFAT)
was performed in accordance with the procedures described in
detail elsewhere [29]. Stool agar plate culture and microscopic
examination (after concentration according to Ritchie) were
performed if not previously available. Baseline assessment also
included routine haematology with WBC differential count and
routine chemistry.
Consenting patients were admitted to the clinic for at least three
days for a close monitoring of side effects; on admission a Case
Report Form (CRF) was filled with the patient’s unique ID
number. Clinical examination and history were carried out on
admission, according to the CRF. Based on the randomization list,
patients were given either ivermectin or thiabendazole. Ivermectin
(tablets 3 mg) was administered at the single dose of 200 mg/kg on
an empty stomach, and patients were instructed to keep fasting for
the following 2 hours. Thiabendazole (tablets 600 mg) was
administered with food, in two daily doses of 25 mg/Kg for two
days. The drug intake was directly observed by a nurse.
The patients were asked to attend the clinic twice after
treatment completion: after one month and after four months.
At both follow-up visits, clinical history and examination were
carried out and a full blood count (FBC) was performed. At the
second visit only, IFAT was performed, and so was a stool agar
plate culture (if positive on recruitment). As was the routine
procedure at CTD laboratory, follow-up serum samples were
tested in parallel with those of the initial diagnosis. If the patient
did not present for the second follow-up visit, the investigator had
to contact her/him and fix another appointment. The second
follow-up visit, at which the efficacy outcomes were assessed, was
considered still valid up to 6 months from the treatment. Patients
who did not present within the 6 months were considered lost to
follow-up.
Objectives
Primary objective was to compare the efficacy of ivermectin,
administered as a single dose of 200 mg/kg, and thiabendazole,
administered in two daily doses of 25 mg/Kg for two days, to cure
strongyloidiasis. Secondary objective was to assess safety and
tolerability of both regimens.
Outcomes
Primary outcome was cure at Time 2 (T2: 4 to 6 months after
recruitment), defined as follows: negative stool agar culture for S.
stercoralis (assessed in case of positivity of any direct stool tests on
recruitment), AND: negative IFAT or decrease of two or more
antibody titers. Secondary outcome was: patients with adverse
reactions (grade 1 to 5 as defined below) to treatment.
All adverse events reported by the patients on days 1 and 2 of
treatment were recorded in the patient’s CRF, and so were
adverse events recorded during scheduled and unscheduled visits.
Adverse events for this study purpose were graded as: 0=None;
1=Mild: any symptoms possibly related to drug, not necessitating
medication; 2=Moderate: any symptoms possibly related to drug,
requiring medication; 3=Serious: requiring treatment to be
discontinued; 4=Near fatal: requiring intensive care; 5=Fatal.
Sample size
The sample size was determined based on the primary outcome.
The trial was designed to detect a difference of efficacy of at least
15% with a study power of 80% and p,0.05 for alternative
hypotheses, 2-sided and with a minimal efficacy of 70% for the less
effective regimen: the required sample size was of 133 subjects in
each group. Considering subjects lost to follow-up, a total of 150
patients for each treatment group was initially planned to be
enrolled.
Author Summary
Strongyloidiasis is the infection caused by the worm
Strongyloides stercoralis. Due to its peculiar life cycle
Strongyloides may remain indefinitely in the host, if not
effectively cured. Although the disease is usually mild, in
case of weakening of the host’s immune defenses the
worm may invade virtually all organs and tissues
(disseminated strongyloidiasis, almost invariably fatal).
The treatment must then reach the goal of the complete
elimination of the parasite. Small size clinical trials showed
similar, high efficacy of the two drugs ivermectin (used as a
single dose) and thiabendazole (used twice daily for two
consecutive days). All trials used as the criterion for cure
the absence of larvae in stool exams. The latter however
may easily miss the infection, falsely suggesting that the
infection has been cured. This trial, using a test detecting
specific Strongyloides antibodies as an additional and more
sensitive diagnostic tool, confirms previous reports: the
two drugs have similar efficacy but ivermectin is better
tolerated and is therefore the first choice. However the
cure rate was lower than 70% for the standard, single dose.
The authors then conclude that a larger, multi center trial
is needed to find the optimal dose schedule of ivermectin.
Ivermectin vs. Thiabendazole for Strongyloidiasis
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Subjects were randomly assigned to one of the following arms
with allocation ratio 1:1. Group A: ivermectin 200 mg/kg in a single
dose. Group B: thiabendazole, 25 mg/Kg b.i.d for two days. The
randomization list was computer-generated by a biostatistician who
wasnotdirectlyinvolvedinanyotheroperationalaspectofthestudy
and handed to the nurse in charge, who was not directly involved in
the study, either, and kept the list in a locked drawer. When a
patient was considered to meet the inclusion criteria and had given
her/his informed consent, the patient was formally recruited by the
study investigator (ZB, AA, GM, MA, MB or SM) who was on duty,
who then reported the patient’s unique ID number and the general
data in the CRF. The nurse in charge (or her delegate in her
absence) was then asked to indicate the allocation group according
to the ID number and treatment was started immediately. As
randomization was not in blocks, there was no way for the
investigator to guess in advance what the next assigned treatment
would be. More rigorous procedures (such as the use of sealed
envelopes labelled with the unique ID number and containing the
indication of allocation) were not judged necessary.
Blinding
This was an open label trial that exclusively relied on lab values
for the assessment of the primary outcome, therefore blinding of
laboratory staff was ensured: the laboratory personnel performing
the analyses (stool culture, serology) had no direct contact with the
investigators and no information as regards the drug administered
to the patient.
Statistical methods
Data were double entered with Epi Info software (CDC Atlanta,
version 3.3.2) and analysed with the same software and with Stata
9.2 (StataCorp LP, College Station, TX 77845 USA). The two
randomised groups were first compared with respect to baseline
demographic and clinical data. Proportions were compared
through Yates’ chi-square test. T test for independent groups
was used for continuous variables. Mann-Whitney U test was used
for non normal variables. The pattern of compliance to treatment
and to follow-up visits was also explored and compliers/non
compliers were compared with respect to baseline data. Patients
with missing values and patients lost during treatment or at follow-
up were to contribute to the analysis only for the time during
which data were available.
The analysis of primary as well as secondary outcomes was
planned on an intention-to-treat basis (ITT) considering all
subjects as originally assigned to the two arms. As all patients
were able to conclude their treatment according to plan, and as we
subsequently excluded from the analysis of efficacy patients lost to
follow-up whose outcome was unknown, this corresponded, de
facto, to a per-protocol (PP) analysis [31].
The proportions of patients with the occurrence of the binary,
primary and secondary outcomes of interest (as defined above) in
each of the two arms were compared through the Yates’ chi-
square test with continuity correction. Fisher’s exact test was
used when appropriate. No subgroup analysis was initially
planned. Subsequently however, a separate analysis was carried
out on subgroups, in order to be able to better compare our
results with those of previous trials based on direct diagnostic
criteria only.
Results
The study started with the recruitment of the first patient on
the 6
th December 2004, while the last one was recruited on the
3
rd August 2006. At that moment, 223 patients had been
included in the study. Recruitment was concluded before the
required sample size was attained. The reason was the obvious
difference in tolerability observed by the investigators between
the two arms. Although this was not an explicitly defined
criterion for the early conclusion of the study (as all observed side
effects were mild to moderate), the recruitment was interrupted
and an interim analysis was carried out in November, 2006, on
the 187 patients who had concluded follow-up. The analysis
showed a very similar cure rate between the two arms, while the
frequency of side effects was much higher in the thiabendazole
arm. Then, on 27
th November, 2006, the decision to stop
recruitment was notified to the Ethical Review Board. After that
date, 11 more patients, previously recruited, presented to follow-
up until January, 2007, when the data lock occurred, after the
second follow-up visit of the last patient (11
thJanuary, 2007),
therefore the final analysis of the primary endpoint concerned
198 subjects.
Participant flow
The flow of patients assessment and enrollment is reported in
the study flow diagram (Figure 1). Briefly, out of 283 patients
initially screened for inclusion, 242 were eligible for inclusion, of
whom 223 gave their written (or their guardians’) informed
consent and were recruited. Of the patients recruited, 115
(51.6%) were randomly assigned to ivermectin arm and 108
(48.4%) to thiabendazole. Follow-up was completed by 198
patients (88.8%), 106 (53.5%) assigned to ivermectin and 92
(46.5%) to thiabendazole.
Baseline data
The main baseline characteristics of the randomized population
(223 patients) is reported in Table 1. None of the observed
differences between the two groups was statistically significant.
In the following table the baseline characteristics of the patients
ultimately analysed for efficacy are compared with those of patients
lost to follow-up (Table 2). All patients lost to follow-up (25/25)
belonged to the group of ‘‘residents overseas’’, which included
immigrants. Compliance to follow-up was higher for ivermectin
(106/115 or 92.2%) than thiabendazole (92/108 or 85.2%), but the
difference was not statistically significant (p=0.15).
Efficacy
We first assessed the efficacy on all 198 subjects included
(Table 3) who were assessed at follow-up. Based on the primary
endpoint (all criteria fulfilled), the subjects cured were 60/106
(56.6%) and 48/92 (52.2%) in ivermectin and thiabendazole
arm, respectively (p=0.53). If we considered as cured, with less
stringent criteria, also the subjects with a partial response
(negative stool culture and decrease of only one IFAT titer),
efficacy would rise to 75/106 (70.8%) and to 67/92 (72.8%),
respectively (p=0.75). If we considered as criteria of cure the
direct methods only (negative stool culture at follow-up in
subjects who were positive at microscopy and/or culture on
recruitment), efficacy would be 30/35 (85.7%) and 35/37
(94.6%), respectively (p=0.21). We then did the same analyses
on the subgroup with IFAT titer $80 (virtually giving no false
positive results) on recruitment (Table 4). On this sub group,
comprising about half the total sample (92 subjects), all criteria
were fulfilled by 32/47 subjects (68.1%) in ivermectin arm and
31/45 (68.9%) in thiabendazole arm (p=0.93). Including
subjects with a partial response as defined above, efficacy would
be 41/47 (87.2%) and 40/45 (88.9%), respectively (p=0.81).
Finally, considering direct methods only in this subgroup, the
Ivermectin vs. Thiabendazole for Strongyloidiasis
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respectively (p=0.22).
Adverse events
As side effects of the two drugs are known to be limited in time,
we considered for this outcome all 223 patients included and not
only those who completed the follow-up. No serious side effect
(grade 3 or more) was observed in any patient. Overall, 103/223
patients complained of any side effect, grade 1 to 2 (Table 5). In
ivermectin arm, side effects were observed in 24/115 patients
(20.9%), versus 79/108 (73.1%) in thiabendazole arm (p=0.00).
Only 5/115 (4.3%) patients in the ivermectin arm presented
effects of grade 2 (requiring medication), while in thiabendazole
arm 43/108 patients (39.8) presented effects of grade 2 (p=0.00).
Dizziness was the most frequently reported side effect both in
thiabendazole arm (57/79 or 72.2%, followed by nausea and
vomiting) and in ivermectin arm (12/24 or 50.0%, followed by day
somnolence) (data not reported in tables).
Discussion
Interpretation
This was the first trial on strongyloidiasis treatment using
serology along with direct methods for case inclusion and
assessment of efficacy. The latter, based on primary outcome,
was lower than 60%, with no significant difference between the
two treatment arms. With less strict criteria (including partial
response as defined above), efficacy would rise to above 70% for
both regimens, still with no significant difference. As the specificity
of IFAT, though very high, is not 100% for the lower dilutions
[29], the inclusion of some false positives may have occurred and
partly explain the low efficacy found. We then analyzed a sub
group of patients who had a serologic titer $80 (virtually giving no
false positive results) [29] on recruitment. Efficacy as defined by
primary outcome, and efficacy including partial response as
defined above, were significantly higher in this subgroup for both
regimens (close to 70% and to 90%, respectively), suggesting a
Figure 1. CONSORT flow diagram. The flow of patients through the randomized clinical trial.
doi:10.1371/journal.pntd.0001254.g001
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patients who had positive stool tests on inclusion, taking culture
negativization as a criterion for cure, the efficacy was close to or
higher than 90% for both regimens, approaching that found by
other studies [15,17–19,22]. Thus, the lower efficacy found by our
study is clearly due to the more strict criteria used to define cure,
that include serology. Our data confirm that serology tends to
decrease in titer within a few months of effective treatment and
can thus be a useful tool for treatment monitoring as was
previously suggested [25–30]. Considering subjects with serologic
titer $80 on inclusion, almost 90% had a drop of titer following
treatment.
Overall evidence
Whatever the criterion used, we were not able to find any
significant difference between thiabendazole and ivermectin at
standard dose for the cure of S. stercoralis infection. This finding
confirms previous, smaller trials [17,18].
Both drugs appeared to be safe, with no serious side effect in
either treatment arm. Nevertheless, thiabendazole caused signif-
icantly more side effects and of higher grade.
Study limitations
This trial was not double blind. This cannot have affected the
assessment of efficacy, as the primary outcome was entirely based
on laboratory investigations and lab staff was kept unaware of the
treatments administered. Contrarily, side effect reporting might
have been influenced both by the investigator’s and the patient’s
knowledge of the drug received. Results are therefore to be taken
with some caution, though the difference between the two arms
was clearly too big to be entirely attributable to bias.
Inclusion criteria allowed the recruitment of patients with
negative direct tests on stool and positive serology at any IFAT
titer. As discussed above, this probably caused some patients
without the infection to be erroneously included with a consequent
underestimation of the efficacy of both drugs. Subsequent analysis
showed that more strict criteria (based on a minimal required
cutoff of dilution) should be followed for trial inclusion. We believe
the analysis of the subgroup of subjects with IFAT titer $80 to
provide the more reliable estimate of efficacy. Given this more
strict inclusion criteria, the analysis still failed to show any
significant difference between the two regimens, but the sample
size was originally calculated only to detect a 15% difference
between the original groups.
Future research
Finally, we still remain with the problem of the lack of a gold
standard to define cure. We think that serology should also have a
Table 4. Outcome at follow-up (month 3
rd–6
th) in the two
arms (92 patients with IFAT titer.=80).
Measures of efficacy Ivermectin Thiabendazole p
All criteria fulfilled 32/47 (68.1%) 31/45 (68.9%) 0.93
Patients with partial
response
1 included
41/47 (87.2%) 40/45 (88.9%) 0.81
Efficacy based on negativization
of stool microscopy and/or culture
22/24 (91.7%) 27/27 (100%) 0.22‘
Inference on proportions based on Yates’ chi-square test, inference on
continuous variables based on Student’s T test, unless otherwise specified.
‘Fisher’s exact test.
1Patients with negative stool and drop of only one antibody titer.
doi:10.1371/journal.pntd.0001254.t004
Table 3. Outcome at follow-up (month 3
rd–6
th) in the two
arms (198 patients who concluded follow-up).
Measures of efficacy Ivermectin Thiabendazole p
All criteria fulfilled 60/106 (56.6%) 48/92 (52.2%) 0.53
Patients with partial
response
1 included
75/106 (70.8%) 67/92 (72.8%) 0.75
Efficacy based on negativization of
stool microscopy and/or culture
30/35 (85.7%) 35/37 (94.6%) 0.19‘
Inference on proportions based on Yates’ chi-square test, inference on
continuous variables based on Student’s T test, unless otherwise specified.
‘Fisher’s exact test.
1Patients with negative stool and drop of only one antibody titer.
doi:10.1371/journal.pntd.0001254.t003
Table 2. Comparison of baseline characteristics of patients
who completed / did not complete follow-up.
Main characteristics
Follow-up
completed (n. 198)
Lost to follow-up
(n. 25) p
Sex M 115 (87.8%) 16 (12.2%) 0.72
Age (Years) (Mean) 43.9 (SD 20.7) 31.8 (SD 9.8) 0.01
Weight (Mean) 67.6 (SD 17.4) 67.3 (SD 15.4) 0.99
Prior residence
overseas
147/198 (74.2%) 25/25 (100%) 0.00
Symptomatic 92/198 (46.5%) 12/25 (48%) 0.95
Eosinophils/mmc
(Mean)
777 (SD 609) 835 (SD 1030) 0.111
IFAT titer (Median) 40 (Q1=20, Q2=160) (80 Q1=40, Q2=160) 0.271
Positive stool agar
culture
85/198 (42.9%) 8/25 (32.0%) 0.69
Positive stool
microscopy
61/198 (30.8%) 8/25 (32.0%) 0.91
Inference on proportions based on Yates’ chi-square test, inference on
continuous variables based on Student’s T test, unless otherwise specified.
1Mann-Whitney U test.
doi:10.1371/journal.pntd.0001254.t002
Table 1. Comparison of randomized groups.
Main characteristics Ivermectin Thiabendazole p
Sex M 70 (60.9%) 61 (56.5%) 0.60
Age (Years) (Mean) 43.9 (SD 20.9) 41.3 (SD 19.3) 0.29
Weight (Mean) 68.5 (SD 18.0) 66.5 (SD 16.3) 0.38
Prior residence overseas 29/115 (25.2%) 22/108 (20.4%) 0.41
Symptomatic 50/115 (43.4%) 54/108 (50.0%) 0.71
Eosinophils/mmc (Mean) 718 (SD 819) 852 (SD 1141) 0.261
IFAT titer (Median) 40 (Q1=20, Q3=160) 60 (Q1=40, Q3=80) 0.891
Positive stool agar culture 35/79 (44.3%) 27/79 (34.2%) 0.22
Positive stool microscopy 34/103 (33.0%) 35/96 (36.5%) 0.71
Inference on proportions based on Yates’ chi-square test, inference on
continuous variables based on Student’s T test, unless otherwise specified.
1Mann-Whitney U test.
doi:10.1371/journal.pntd.0001254.t001
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local transmission, where the interpretation of the results is not
potentially confounded by reinfection. While awaiting alternative
diagnostic methods such as real time PCR [32] to become a
reliable alternative, the best option is probably the combination of
direct with indirect methods, but the latter need further study to
identify the optimal serologic test and cutoff for diagnosis, trial
inclusion and treatment follow-up.
Ivermectin is the treatment of choice due to better tolerability,
but the single dose efficacy is sub optimal. Some guidelines and the
WHO drug formulary have already shifted to a new schedule
(200 mg/Kg/day for two consecutive days) [11,12], while some
experts recommend the repetition of treatment after two weeks, on
ground of the parasite life cycle [33]. Though it seems reasonable
to expect that the use of an increased dose would improve the
efficacy of ivermectin, neither of these alternative regimens has
ever been validated by a randomized trial to our knowledge, and
the last published trial [13] failed to show any significant difference
between the single dose and two doses two weeks apart.
Considering that no truly promising new drug is in the pipeline,
we are planning a multi center trial on different dose schedules of
ivermectin.
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